Master the Signal.Navigate Complexity.Create Cures.
A clinical-stage immunotherapy company developing engineered interleukins designed to precisely modulate the immune system.
About
At MedicennaWe Start witha Powerful Idea.
The best way to treat immune-driven disease is to speak the same language as the immune system itself.
We utilize directed evolution and AI-driven rational design to re-engineer natural interleukins, the immune system's own messengers, and create precision interleukin-based therapies for cancer and other serious immune-driven diseases, including autoimmune and inflammatory disorders.
We are committed to delivering first- and best-in-class treatment options for people living with these challenging diseases.
One Vision.Multiple Platforms.
Infinite Hope.
Medicenna has developed three interleukin-based platforms, Superkine™, BiSKIT™ and T-MASK™. Our platforms refine the properties of native interleukins to fine-tune potency, selectivity and tissue-targeting, with the goal of improving therapeutic outcomes and tolerability for patients.
Partner Ready Pipeline
Clinical Trials
How We Are Makingan Impact Today
Medicenna is currently enrolling patients in the Phase 1/2 ABILITY-1 study for patients with advanced solid tumors to evaluate MDNA11, a long-acting beta-enhanced IL-2 Superkine that is designed to primarily signal through the IL-2 beta receptor found on cancer-fighting immune cells.
Medicenna recently announced a collaboration with Fondazione Melanoma Onlus in Italy to evaluate MDNA11 in patients with high-risk surgically resectable stage III melanoma prior to surgery. NEO-CYT is designed to evaluate the potential of MDNA11 to enhance the efficacy of standard-of-care cancer immunotherapy in the neoadjuvant setting.
Medicenna completed a Phase 2b study in the deadliest form of brain cancer, recurrent glioblastoma. The data from the trial demonstrated that single treatment with their phase-3 ready immunotherapy doubled the median overall survival.
View Clinical Trials
Partnerships are Core to Our Strategy
Interested in learning more about our assets? At Medicenna we are open to discussions on co-development opportunities, outlicensing and research collaborations.
Partnerships
Medicenna has a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate MDNA11 in combination with pembrolizumab.
The collaboration includes a Phase 1/2 study evaluating MDNA11 in combination with pembrolizumab in patients with advanced solid tumors.
Medicenna has partnered with Fondazione Melanoma Onlus in an investigator-initiated trial 'NEO-CYT' that is assessing MDNA-11 in combination with nivolumab with and without ipilimumab in high-risk, surgically resectable stage III cutaneous melanoma in the neoadjuvant setting. By treating patients prior to surgery NEO-CYT is designed to assess whether addition of MDNA11 to the standard of care can deepen the responses associated with improved long-term outcomes.
Investor Relations
Interested in learning more about our assets? At Medicenna we are open to discussions on co-development opportunities, outlicensing and research collaborations.
April 21, 2026
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
April 14, 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 9, 2026